Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
Latest Information Update: 21 May 2021
At a glance
- Drugs Olorinab (Primary)
- Indications Irritable bowel syndrome
- Focus Pharmacokinetics
- Sponsors Arena Pharmaceuticals
- 13 May 2021 Status changed from recruiting to discontinued. Reason the study was stopped: Strategic business decision.
- 14 Dec 2020 New trial record